The Globe and Mail reports in its Friday, Feb. 7, edition that TD Cowen analyst Cherilyn Radbourne is keeping her "buy" recommendation for ATS intact. The Globe's David Leeder writes in the Eye On Equities column that Ms. Radbourne bumped her share target ahead by $2 to $58. Analysts on average target the shares at $49.29. Ms. Radbourne says in a note: "Bookings of $883-million, the second highest on record, surpassed even our Street-high estimate. ATS now has record backlogs in life sciences and food and beverage, and has made new inroads in robotic surgery. We also believe that there is interesting upside optionality developing over time in nuclear. Unfortunately, the disputed amount owing from ATS's large EV customer (approximately $3.50/share) remains outstanding." The Globe reported on Sept. 6 that National Bank Financial analyst Maxim Sytchev continued to rate ATS "outperform." The shares could then be had for $34.47. The Globe reported on Oct. 2 and Jan. 28 that Ms. Radbourne was maintaining her "buy" recommendation for ATS. The shares could then be had for $39.37 and $39.99.